Table 2.
Factors at presentation and during follow-up influencing composite kidney failure events (ESKD or eGFR halving) by univariate and multivariate Cox regression
| Characteristic | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P Value | HR | 95% CI | P Value | |
| Age (per 10 yr) | 1.10 | 0.93 to 1.30 | 0.26 | |||
| Sex (women versus men) | 0.79 | 0.53 to 1.18 | 0.24 | |||
| Haas classification | ||||||
| I/II | 1 | Reference | 1 | Reference | ||
| III | 2.61 | 0.89 to 7.62 | 0.10 | 0.59 | 0.11 to 3.27 | 0.54 |
| IV | 5.02 | 1.76 to 14.37 | 0.01 | 1.99 | 0.43 to 9.24 | 0.38 |
| V | 18.87 | 6.50 to 54.74 | <0.001 | 3.04 | 0.61 to 15.28 | 0.18 |
| Baseline eGFR (per 10 ml/min per 1.73 m2) | 0.67 | 0.62 to 0.73 | <0.001 | 0.76 | 0.66 to 0.91 | 0.002 |
| Baseline proteinuria (per g/d) | 1.13 | 1.07 to 1.18 | <0.001 | 1.02 | 0.92 to 1.13 | 0.79 |
| Proteinuria at month 6 (per g/d) | 1.85 | 1.64 to 2.09 | <0.001 | 1.53 | 1.27 to 1.84 | <0.001 |
| Baseline SBP (per 10 mmHg) | 1.31 | 1.17 to 1.48 | <0.001 | 0.81 | 0.64 to 1.03 | 0.09 |
| SBP at month 6 (per 10 mmHg) | 1.64 | 1.38 to 1.95 | <0.001 | 1.36 | 1.05 to 1.77 | 0.02 |
| Immunosuppressive therapy (yes or no) | 2.37 | 1.55 to 3.60 | <0.001 | 1.73 | 0.88 to 3.38 | 0.11 |
| Uric acid (per mg/dl) | 1.28 | 1.17 to 1.40 | <0.001 | 1.09 | 0.92 to 1.30 | 0.34 |
HR, hazard ratio; 95% CI, 95% confidence interval.